Downregulated expression of plasminogen activator inhibitor-1 augments myocardial neovascularization and reduces cardiomyocyte apoptosis after acute myocardial infarction.

[1]  Shawdee Eshghi,et al.  Down-regulation of Plasminogen Activator Inhibitor 1 Expression Promotes Myocardial Neovascularization by Bone Marrow Progenitors , 2004, The Journal of experimental medicine.

[2]  K. Preissner,et al.  Induction of Apoptosis in Vascular Cells by Plasminogen Activator Inhibitor-1 and High Molecular Weight Kininogen Correlates with Their Anti-Adhesive Properties , 2003, Biological chemistry.

[3]  P. Carmeliet,et al.  Plasmin activity is required for myogenesis in vitro and skeletal muscle regeneration in vivo. , 2002, Blood.

[4]  L. Devy,et al.  The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  S. Homma,et al.  Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function , 2001, Nature Medicine.

[6]  D. Lawrence,et al.  Inhibition of Angiogenesis in Vivo by Plasminogen Activator Inhibitor-1* , 2001, The Journal of Biological Chemistry.

[7]  P. Carmeliet,et al.  Urokinase-dependent plasminogen activation is required for efficient skeletal muscle regeneration in vivo. , 2001, Blood.

[8]  L. Khachigian,et al.  Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. , 2000, The Journal of clinical investigation.

[9]  A. Luttun,et al.  Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure , 1999, Nature Medicine.

[10]  D. Dichek,et al.  Optimizing vascular gene transfer of plasminogen activator inhibitor 1. , 1999, Human gene therapy.

[11]  K. Almholt,et al.  Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. , 1998, Current opinion in cell biology.

[12]  P. Carmeliet,et al.  Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[13]  O. Carpén,et al.  Plasminogen activator inhibitor-1 in neointima of vein grafts: its role in reduced fibrinolytic potential and graft failure. , 1997, Circulation.

[14]  K. Preissner,et al.  Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. , 1997, Experimental cell research.

[15]  G. F. Joyce,et al.  A general purpose RNA-cleaving DNA enzyme. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Clowes,et al.  Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinases-2 increase after arterial injury in rats. , 1997, Circulation research.

[17]  R. V. van Suylen,et al.  Determinants of coronary reserve in rats subjected to coronary artery ligation or aortic banding. , 1996, Cardiovascular research.

[18]  S. Thompson,et al.  Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. , 1996, Circulation.

[19]  Steingrimur Stefansson,et al.  The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin , 1996, Nature.

[20]  M. Daemen,et al.  Time-related normalization of maximal coronary flow in isolated perfused hearts of rats with myocardial infarction. , 1996, Circulation.

[21]  K. Schmid,et al.  Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[22]  A. Shapiro,et al.  Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. , 1992, The New England journal of medicine.

[23]  D. Loskutoff,et al.  Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Huber,et al.  A Decrease in Plasminogen Activator Inhibitor-1 Activity after Successful Percutaneous Transluminal Coronary Angioplasty Is Associated with a Significantly Reduced Risk for Coronary Restenosis , 1992, Thrombosis and Haemostasis.

[25]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[26]  M. Shirotani,et al.  Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. , 1996, American heart journal.

[27]  D. Lawrence,et al.  The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. , 1996, Nature.